Novel Investigation of SARS-CoV-2 in COVID-19 Survivors' 1

Semen in Surabaya, Indonesia 2

Supardi Supardi,^{1,2} Reviany V. Nidom,^{3,4}* Eni M. Sisca,¹ Jefry A. Tribowo,¹ Patricia S. Kandar,¹ Joice M. Budiharto,¹ Eko Siswidiyanto,¹ Maitra Djiang Wen,^{6,7,8} Tiara 3

4

Kirana,⁸ Astria N. Nidom,³ Arif N. M. Ansori,³ Irine Normalina,³ Setyarina Indrasari,^{3,4} 5

- **Reny I'tishom**^{1,5} 6
- 7

8 ¹Andrology Specialist Program, Faculty of Medicine, Universitas Airlangga, Surabaya,

- 9 Indonesia.
- ²Dr. Soetomo General Hospital, Surabaya, Indonesia. 10
- ³Coronavirus and Vaccine Formulation Research Group, Professor Nidom Foundation, 11
- 12 Surabaya, Indonesia.
- ⁴Riset AIRC Indonesia, Surabaya, Indonesia. 13
- 14 ⁵Department of Biomedical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, 15 Indonesia.
- ⁶Wahidin Sudiro Husodo General Hospital, Mojokerto, Indonesia. 16
- ⁷Signum Fertility Clinic, Husada Utama Hospital, Surabaya, Indonesia. 17
- 18 ⁸Bocah Indonesia, Primaya Hospital, Tangerang, Indonesia.
- 19
- 20 Correspondence should be addressed to Reviany V. Nidom; reviany@pnfinstitute.org
- 21

22 Abstract

23

24 The emergence and the widespread of Coronavirus disease 2019 (COVID-19) demands an 25 accurate detection method to establish a diagnosis. Real-time polymerase chain reaction 26 (real-time PCR) is accounted for the perfect point of reference in detecting this virus. The 27 notion that this virus also invades the male reproductive tract requires further investigation to 28 prove the presence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in the 29 semen. This investigation was designed to detect SARS-CoV-2 in COVID-19 survivors' 30 semen. This study design was a cross-sectional examination and conducted between 31 November 2020 and March 2021 in the Andrology Unit of Dr. Soetomo General Hospital and 32 Professor Nidom Foundation, both located in the City of Surabaya, Indonesia. The sample 33 was 34 male participants aged above 18 years old and had been confirmed COVID-19 by 34 nasopharyngeal swab PCR test. Part of the semen was taken for real-time PCR testing with 35 the QuantStudio 5 Applied Biosystem (AB) PCR machine and the kits utilized were the 36 STANDARD M nCOV Real-Time Detection Kit and mBioCov-19 RT-PCR Kit. 37 Furthermore, the mean of participants' ages was 35.74 years old with 25% of them had had a 38 history of primary infertility and 21.8% of secondary infertility. From the real-time PCR 39 COVID-19 of the semen examination, this investigation found that 27 participants had been negatives (74.4%), six inconclusive (17.6%), and one positive (3%) of SARS CoV-2. In 40 41 summary, SARS-CoV-2 could be found in the semen of COVID-19 survivors. This should be 42 a concern for the potential impact of COVID-19 in male fertility and the possibility of 43 transmission reproductively.

- 44
- 45
- 46
- 47

48 **1. Introduction**

49

50 COVID-19 occurs as the result of contagiousness from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spread abruptly and became a global pandemic since 51 52 December 2019 as the first report of the emergence of this virus in Wuhan [1,2]. As of June 53 2021, there is around 170 million confirmed prevalence of COVID 19 infection globally with 54 more than 3.5 million global deaths. To be specific, Indonesia has about 1.8 million cases and 55 around 50 thousand deaths [1,2,3,4,5]. The involvement of this disease causes a very broad 56 impact and clinical manifestations that vary, ranging from asymptomatic to systemic 57 dysfunction [6,7]. Furthermore, SARS-CoV-2 involves angiotensin II converting enzymes 58 (ACE2) as a receptor for entering into the cells. This expression of ACE 2 is found in the 59 intestine, kidney, and testicle [8]. Although ACE2 expression is present in the testes, the 60 direct involvement of SARS-CoV-2 infection in the testes or male genital tract is still in 61 question [9].

62 Various testing approaches were developed to detect this virus. An accurate and fast detection method is needed as part of preventive and curative efforts [10]. Until recently, 63 64 three types of diagnostic tests have been developed, namely reverse transcription-polymerase 65 chain reaction (RT-PCR) assay, antibody detection and tissue culture isolation [11]. The most highly recommended, which puts a highly accurate benchmark, uses a nucleic acid-based 66 67 approach such as the polymerase chain reaction (PCR) method as it has rapid, sensitive, and 68 specific virus detection capabilities, even PCR can detect early SARS-CoV-2 infection. PCR 69 analysis utilizes specimens generated from saliva; the swabbing activity of nasal, trachea and 70 nasopharyngeal; tissues of lungs; blood; semen; and even; excrement. [12,13]. The extraction 71 process of ribonucleic acid (RNA) in the specimen starts from the purification process of 72 total RNA into viral RNA and host RNA, then continued by reversed transcription into the 73 complementary DNA (cDNA) and followed by amplification using the polymerization of 74 chain reaction which is the foundation of real time reverse transcription-polymerase chain 75 reaction (rRT-PCR) examination. [14]. Although rRT-PCR is the most widely used and 76 recommended as the barometer of SARS COV-2 diagnostics, it also has drawbacks. Errors in 77 the preparation, analysis, and interpretation stages will give false positive or false negative or 78 inconclusive rRT-PCR results [15,16].

Unlike rRT-PCR examination of nasopharyngeal specimens which is routinely performed,
the use of rRT-PCR in semen specimens is still limited and is more for research purposes.
There were various studies discussing COVID-19 rRT-PCR in semen [11,13,15,16,17].
Among these various studies, only two studies detected SARS-CoV-2 in the semen [18,19].
Therefore, this investigation was the novel finding in Indonesia to examine the semen of male
COVID-19 survivors using rRT-PCR test method to confirm whether SARS-COV-2 was
found in the men reproductive tract of the survivors.

86

87 2. Materials and Methods

88
2.1. Design study and participants. This research is a cross-sectional examination. This
90 investigation was conducted between November 2020 and March 2021 in the Andrology Unit
91 of Dr. Soetomo Regional Hospital and in the Professor Nidom Foundation, both located in
92 Surabaya, Indonesia. A total of 34 male participants were registered as research subjects.
93 Inclusion criteria were males older than 18 years old, had been confirmed COVID-19 by
94 nasopharyngeal PCR test, and already in the recovery phase. This research was ethically

95 evaluated with an ethical exemption with the reference number 96 274/EC/KEPK/FKUA/2020 from the Faculty of Medicine, Universitas Airlangga.

of



97

Figure 1. Location of the Study. This study conducted in the Andrology Unit, Dr.Soetomo
Regional Hospital Surabaya and Professor Nidom Foundation,
Surabaya, Indonesia.

101

102 *2.2. Data collection.* This investigation performed historical consideration and semen 103 analysis on the participants who met the inclusion criteria. Participants were then instructed 104 to abstinence 2-7 days and wash their hands before doing masturbation for the semen 105 collection.

106 2.3. Real-Time PCR. The examination was implemented using RT-PCR with QuantStudio 5 107 Applied Biosystem (AB) PCR machine, the kit applied was STANDARD M nCOV Real-108 Time Detection Kit (Lot #MNCO0120026) and MBioCoV-19 RT-PCR Kit (Lot # 6900820) 109 carried out at the Research Group of Coronavirus and Vaccine Formulation, at Professor 110 Nidom Foundation, Surabaya, Indonesia. This investigation utilized a kit based on Taqman 111 probe real time fluorescent PCR technology. The foundation of PCR examination was the 112 transcription of coronavirus RNA into cDNA by reverse transcriptase as the first step, then 113 cDNA was employed as a framework for PCR amplification.

114 PCR reaction simultaneously applied activities of polymerase such as DNA polymerase and 115 exo-nuclease. The detachment of both fluorophore and quencher along with the activity of 116 dicer, which has the capability to discredit the TaqMan probe, provoke the instrument to 117 indicate the signal of fluorescence; for example, new coronavirus ORP1ab (RdRp) gene was 118 detected by FAM channel qualitative, coronavirus E gene was identified by JOE (VIC or 119 HEX) channel qualitative indication, and internal reference was recognized by CY5 channel 120 detection. In preventing the contamination of amplification products, dUTP and UNG 121 enzymes were employed by this kit. Positive criteria were detected if 2 gene (E and RdRP) 122 \leq 36. If the results only found in E gene \leq 36, it meant that the inconclusive. Negative criteria 123 are E and RdRP not detected.

Moreover, PCR examination was carried out in two stages. In the first stage, PCR examination of semen sample code 1-15 was performed on January, 2021 and in the second

stage, PCR for semen sample code 16-34 was implemented on March, 2021. Before the rRT
 PCR examination was conducted, the specimens were stored in a refrigerator at 4°C.

128 2.4. Statistical analysis. The data from anamnesis and the interpretation of PCR results that

had been collected were analyzed and grouped by demographics, the rRT-PCR results, the

130 rRT-PCR results based on the degree of symptoms, the duration of time between

131 nasopharyngeal PCR and semen PCR, and lastly, the symptoms.

132

133 **3. Results**

134

In this investigation, the rate of male COVID-19 survivors' age was 37.60±7.834, while for their spouses was 37.44±5.525. The average duration of marriage was 9.11 years with 90% of them were married. Furthermore, the primary infertility rate was 44.4%, and, for secondary infertility, it was 22.2% (Table 1). In the results of real-time PCR COVID-19 in the semen, it was found that 27 participants were negative (74.4%), 6 participants were inconclusive (17.6%), and 1 participant was positive (3%) (Table 2 and Figure 1).

Meanwhile, rRT-PCR examinations based on the degree of COVID-19 symptoms were classified into 4 groups, they were asymptomatic with negative semen rRT-PCR result in 13 participants (38.23%), asymptomatic COVID-19 with positive semen rRT-PCR result in 1 participant (2.94%), mild symptoms with negative semen rRT-PCR result in 11 participants (32.35%), mild symptoms with inconclusive semen rRT-PCR result in 6 participants (17.64%), and moderate symptoms with negative semen rRT-PCR result in 3 participants

147 (8.82%) (Table 3 and Figure 2).

148 Furthermore, the average of interval duration between positive or inconclusive rRT for

149 nasopharyngeal PCR and rRT for semen PCR with positive or inconclusive results was

- 150 113.28 days. The fastest interval duration between positive and inconclusive nasopharyngeal
- 151 PCR and semen PCR was 53 days, while the longest interval duration to produce positive or
- 152 inconclusive PCR was 186 days (Table 4).

Based on the severity classification of COVID-19 according to WHO [18], this study

- distributed the symptoms of COVID 19 into asymptomatic, mild, moderate and severe
- 155 COVID 19 (Table 5). There were not any participants in this study who had a severe 156 symptom of COVID-19.
- 157
- 158 Table 1: Demographic Characteristics of Participants

Variable	
Total participants (n)	10
Mean age	37.60±7.834
Mean couples age	37.44±5.525
Mean marriage	9.11
duration	
Marital Status	
Married	9 (90%)
Not Married	1 (10%)
Primary Infertility	
Yes	4 (44.4%)
No	5 (55.6%)
Secondary Infertility	
Yes	2 (22.2%)
No	7 (77.8%)

159 160

161 Table 2: Semen rRT-PCR Results.

Code	Ε	RdRP	IC	Interpretation
S 1	-	-	23.91	Negative
S2	-	-	21.11	Negative
S 3	-	-	26.07	Negative
S4	-	-	21.24	Negative
S5	-	-	20.21	Negative
S6	-	-	20.49	Negative
S 7	-	-	21.95	Negative
S 8	-	-	25.59	Negative
S 9	-	-	22.87	Negative
S10	32.64	36.16	23.31	Positive
S11	-	-	26.58	Negative
S12	-	-	27.96	Negative
S13	-	-	25.29	Negative
S14	-	-	24,23	Negative
S15	-	-	26.41	Negative
S16	-	-	26.88	Negative
S17	-	-	19.35	Negative
S18	-	-	21.11	Negative
S19	-	35.86	21.57	Inconclusive
S20	-	-	22.9	Negative
S21	-	35.99	20.47	Inconclusive
S22	33.77	42.62	19.36	Inconclusive
S23	-	35.64	23.78	Inconclusive
S24	-	34.99	17.52	Inconclusive
S25	-	27.65	21.19	Inconclusive
S26	-	-	24.51	Negative
S27	_	-	24.05	Negative
S28	-	-	26.45	Negative
S29	-	-	27.47	Negative
S30	-	-	23.5	Negative
S 31	-	-	25.33	Negative
S32	-	-	24.43	Negative


S33	-	-	24.91	Negative
S34	-	-	26.86	Negative

162

163 Table 3: Interval Duration of rRT-PCR Examination in Nasopharyngeal and Semen

Sample	rRT PCR Semen (n = 7)	rRT PCR Nasopharyngeal	Interval Duration
S10	Positive	Positive	121 days
S19	Inconclusive	Positive	177 days
S21	Inconclusive	Positive	126 days
S22	Inconclusive	Positive	59 days
S23	Inconclusive	Positive	186 days
S24	Inconclusive	Positive	53 days
S25	Inconclusive	Positive	71 days
Total			793 days
Mean			113.28 days

164



165 166

5 Figure 2. rRT-PCR of S10 with IC: 23.31.

167


168 Table 4. Distribution of PCR results based on disease severity.

169

COVID-19 Symptoms	Asymptomatic (n=14)	Mild (n= 20)	Moderate	Severe
Semen rRT-PCR				
rRT-PCR Negative	13 (38.23%)	11 (32.35%)	3 (8.82%)	NA
rRT-PCR Positive	1 (2.94%)	0	0	NA
rRT-PCR Inconclusive	0	6 (17.64%)	0	NA
Total	14 (41.17%)	17 (50%)	3 (8.82%)	NA

170 NA: Not Available

171



172 173 174

175 Table 5: COVID-19 symptoms of participants

Symptoms	Total (n=34)
Asymptomatic	14 (41.18%)
Mild	
Anosmia	8 (23.53%)
Hypogeusia	1 (2.94%)
Flu-like Syndrome (fever, cough, cold,	
and sore throat)	10 (29.41%)
Gastrointestinal Symptoms (vomit and	
diarrhea)	2 (5.88%)
Insomnia	
	1 (2.94%)
Orchitis	
	1 (2.94%)
Moderate	
Shortness of Breath	3 (8.82%)
Pneumonia on Chest X-ray	3 (8.82%)

176

177 **4. Discussion**

178

179 In this examination, as the mean of participants' age was 37.7 years, the oldest was about 180 50's years old and the youngest was about 20's years old. Most of the participators were 181 sexually active and had children. Age is one of the prognostic factors of participants infected

with COVID-19, as the older is the age, the greater is the possible risk of worseningsymptoms [20,21,22].

184 Meanwhile, the results of the semen PCR in this examination were inconclusive for 6

participants (17.6%). In Gacci *et al.* (2021) research, they revealed one participant was

186 inconclusive [18], while the study of Bhattacharya *et al.* (2020) stated that the results of rRT

187 nasopharyngeal swab were inconclusive around 5%. There are several factors that affect the 188 inconclusive PCR results from the virologic perspective; due to RNA extraction errors.

inconclusive PCR results from the virologic perspective; due to RNA extraction errors,
 inadequate sample quality (internal housekeeping genes were not detected in RT-PCR), other

beta corona virus infections, very early or late stage of infection, differences in analytic

sensitivity in E and S gene or RdRP, distinction in the specificity of screening and confirming

gene PCRs. In addition, it can be caused as well because of the improper preanalytical stage in the form of sampling and no cold chain provision leading to RNA degradation, poor quality of transporter medium, poor storage space, and lack of amplification in internal

195 control or housekeeping genes [23].

196 Correspondingly, there was only one participant with positive semen rRT-PCR in this study.

- 197 The time span between positive nasopharyngeal rRT-PCR and positive semen rRT-PCR in
- this participant was 121 days. This participant was about 30's years old, married, and had 2 children. He had asymptomatic on COVID-19 and no history of any systematic disease. He
- 200 had central obesity according to the Asian-Pacific criteria [24].


201 Furthermore, Li et al (2020) stated that SARS COV-2 was found in semen in two positive 202 participants based rRT PCR examination in the recovery phase, while other 4 participants 203 were detected positive in the semen during the acute phase. In this study, the discovery of one 204 participant who was positive for SARS COV-2 in the semen has similarities with the study of 205 Gacci et al. (2021) where there was only one participant who was positive for SARS COV-2 206 in the semen, but when the nasopharyngeal PCR test was evaluated, the results were negative 207 [18]. Whereas in this investigation, a nasopharyngeal PCR for reevaluation was not 208 performed on this patient.

Additionally, one participant in this study complained on the testicular pain at initial symptom onset. In other study, it was found there were 6 cases of orchitis from the autopsy of SARS patients [25]. This spread in the reproductive tract is probably related to viral loads in the body and related to the infectious process (Figure 3 and Figure 4) [26].

Since most of the participants were detected negative for semen PCR (74.4%), this was probably because the recruited participants had already passed the recovery phase. Furthermore, the results of rRT PCR were more often negative because there was only <1% chance of detecting positivity in the semen [15,16].

Finally, the weakness in this current investigation was that the transport of the samples did not use a cold chain box, thus, there was an opportunity for errors occurring at the preanalytic stage. This PCR examination was not examined when the sample first received, instead it was stored in the refrigerator for several days. Participants with positive PCR results in semen were no longer confirmed by nasopharyngeal PCR, therefore, it was not

known whether there was a recurrent positive.



223

Figure 4: Feasible scenarios and viral entry action for SARS-CoV-2 in semen. Infection of this virus is dependent on both TMPRSS2 and ACE2 expression for the entry into the host cell. This figure created with BioRender.

227

228 **5.** Conclusions

In summary, SARS-CoV-2 could be found in the semen of COVID-19 survivors. It should be noted that PCR is influenced by preanalytical, analytical, and interpretive circumstances. The SARS-CoV-2 existence in the semen sample requires to be further evaluated in future study, as this could be a concern for the consequences of COVID-19 on male fertility status and the possibility of sexual transmission.

235 Data Availability

The utilized data to contribute in this investigation are available from the corresponding

- author on reasonable request.
- 238

239 **Conflicts of Interest**

- 240 The authors declare that there is not any conflict of interest in this study.
- 241

242 Acknowledgments

The authors would like to convey gratitude to all employees at the Andrology Unit, Dr. Soetomo Regional Hospital Surabaya and the Department of Biomedical Science in the Faculty of Medicine of Universitas Airlangga, specifically to all participators, colleagues, and acquaintances contributed in this study for their tremendous assistance to complete this investigation. This research was fully supported by Universitas Airlangga's grant for COVID-19 Research (Grant Number: 664/UN.3.14/PT/2020) and the Professor Nidom Foundation, Surabaya, Indonesia (Grant Number: 006/PNF-RF/10/2020).

250

251 **References**

[1] Nidom RV, Indrasari S, Normalina I, Nidom AN, Afifah B, Dewi L, Putra AK, Ansori
ANM, Kusala MKJ, Alamudi MY, Nidom CA. An updated investigation prior to
COVID-19 vaccination program in Indonesia: Full-length genome mutation analysis of
SARS-CoV-2. bioRxiv. 2021.

- [2] Ansori ANM, Nidom RV, Kusala MKJ, Indrasari S, Normalina I, Nidom AN, Afifah B,
 Sari KB, Ramadhaniyah NL, Alamudi MY, Cahyaningsih U, Santoso KP, Kuswanto H,
 Nidom CA. Viroinformatics investigation of B-cell epitope conserved region in SARSCoV-2 lineage B. 1.1. 7 isolates originated from Indonesia to develop vaccine candidate
 against COVID-19. J Pharm Pharmacogn Res. 2021; 9(6): 766-779.
- [3] Normalina I, Indrasari S, Nidom RV, Kusala MKJ, Alamudi MY, Santoso KP,
 Rachmawati K, Nidom CA. Characterization of the spike glycoprotein and construction
 of an epitope-based vaccine candidate against Indonesian SARS-CoV-2: *In silico* study.
 Sys Rev Pharm. 2020; 11(7): 404-413.
- [4] Nidom RV, Indrasari S, Normalina I, Kusala MKJ, Ansori ANM, Nidom CA.
 Investigation of the D614G mutation and antibody-dependent enhancement sequences in indonesian SARS-CoV-2 isolates and comparison to southeast Asian isolates. Sys Rev Pharm. 2020; 11(8), 203-213.
- [5] Nidom RV, Ansori ANM, Indrasari S, Normalina I, Kusala MKJ, Saefuddin A, Nidom
 CA. Recent updates on COVID-19 vaccine platforms and its immunological aspects: A
 review. Sys Rev Pharm. 2020; 11(10): 807-818.
- [6] Ansori ANM, Kusala MKJ, Normalina I, Indrasari S, Alamudi MY, Santoso KP,
 Rachmawati K, Nidom CA. Immunoinformatic investigation of three structural protein
 genes in Indonesian SARS-CoV-2 isolates. Sys Rev Pharm. 2020; 11(7): 422-434.
- [7] Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response.
 Curr Probl Cardiol. 2020; 45(8): 100618.
- [8] Paoli D, Pallotti F, Colangelo S, Basilico F, Mazzuti L, Turriziani O, Antonelli G, Lenzi
 A, Lombardo F. Study of SARS-CoV-2 in semen and urine samples of a volunteer with
 positive naso-pharyngeal swab. J Endocrinol Invest. 2020; 43(12): 1819-1822.
- [9] Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, Ma H, Chen W, Lin Y, Zheng Y, Wang J,
 Hu Z, Yi Y, Shen H. Clinical characteristics of 24 asymptomatic infections with
 COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;
 63(5): 706-711.
- [10] Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: Issues affecting
 the results. Expert Rev Mol Diagn. 2020; 20(5): 453-454.
- [11]Emery SL, Erdman DD, Bowen MD, Newton BR, Winchell JM, Meyer RF, Tong S,
 Cook BT, Holloway BP, McCaustland KA, Rota PA, Bankamp B, Lowe LE, Ksiazek
 TG, Bellini WJ, Anderson LJ. Real-time reverse transcription-polymerase chain reaction
 assay for SARS-associated coronavirus. Emerg Infect Dis. 2004; 10(2): 311-6.
- [12] Nascimento Junior JAC, Santos AM, Oliveira AMS, Guimarães AG, Quintans-Júnior LJ,
 Coutinho HDM, Martins N, Borges LP, Serafini MR. Trends in MERS-CoV, SARSCoV, and SARS-CoV-2 (COVID-19) diagnosis strategies: A patent review. Front Public
 Health. 2020; 8: 563095.
- [13] Paoli D, Pallotti F, Nigro G, Mazzuti L, Hirsch MN, Valli MB, Colangelo S, Mastroianni
 CM, Antonelli G, Lenzi A, Turriziani O, Lombardo F. Molecular diagnosis of SARS CoV-2 in seminal fluid. J Endocrinol Invest. 2021: 1-10.
- [14] Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics in context. Sci Transl Med.
 2020; 12(546): eabc1931.
- [15] Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities
 in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab
 Med. 2020; 58(7): 1070-1076.
- 302 [16]Lippi G, Henry BM, Sanchis-Gomar F, Mattiuzzi C. Updates on laboratory
 303 investigations in coronavirus disease 2019 (COVID-19). Acta Biomed. 2020; 91(3):
 304 e2020030.

- [17]Gonzalez DC, Khodamoradi K, Pai R, Guarch K, Connelly ZM, Ibrahim E, Arora H,
 Ramasamy R. A systematic review on the investigation of SARS-CoV-2 in semen. Res
 Rep Urol. 2020; 12: 615-621.
- [18]Gacci M, Coppi M, Baldi E, Sebastianelli A, Zaccaro C, Morselli S, Pecoraro A, Manera
 A, Nicoletti R, Liaci A, Bisegna C, Gemma L, Giancane S, Pollini S, Antonelli A, Lagi
 F, Marchiani S, Dabizzi S, Degl'Innocenti S, Annunziato F, Maggi M, Vignozzi L,
 Bartoloni A, Rossolini GM, Serni S. Semen impairment and occurrence of SARS-CoV-2
 virus in semen after recovery from COVID-19. Hum Reprod. 2021; 36(6): 1520-1529.
- [19] Ruan Y, Hu B, Liu Z, Liu K, Jiang H, Li H, Li R, Luan Y, Liu X, Yu G, Xu S, Yuan X,
 Wang S, Yang W, Ye Z, Liu J, Wang T. No detection of SARS-CoV-2 from urine,
 expressed prostatic secretions, and semen in 74 recovered COVID-19 male patients: A
 perspective and urogenital evaluation. Andrology. 2021; 9(1): 99-106.
- [20] Li D, Jin M, Bao P, Zhao W, Zhang S. Clinical characteristics and results of semen tests
 among men with Coronavirus Disease 2019. JAMA Netw Open. 2020; 3(5): e208292.
- [21] Jang JG, Hur J, Choi EY, Hong KS, Lee W, Ahn JH. Prognostic factors for severe
 Coronavirus Disease 2019 in Daegu, Korea. J Korean Med Sci. 2020; 35(23): e209.
- [22] Izcovich A, Ragusa MA, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A,
 Ceirano A, Espinosa F, Saavedra E, Sanguine V, Tassara A, Cid C, Catalano HN,
 Agarwal A, Foroutan F, Rada G. Prognostic factors for severity and mortality in patients
 infected with COVID-19: A systematic review. PLoS One. 2020; 15(11): e0241955.
- [23]Bhattacharya S, Vidyadharan A, Joy VM. Inconclusive SARS-COV-2 reverse
 transcription-polymerase chain reaction test reports: Interpretation, clinical and infection
 control implications. J Acad Clin Microbiol. 2020; 22(1): 59-61
- [24] Lim JU, Lee JH, Kim JS, Hwang YI, Kim TH, Lim SY, Yoo KH, Jung KS, Kim YK,
 Rhee CK. Comparison of World Health Organization and Asia-Pacific body mass index
 classifications in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017; 12: 2465-2475.
- [25]Xu J, Qi L, Chi X, Yang J, Wei X, Gong E, Peh S, Gu J. Orchitis: A complication of
 severe acute respiratory syndrome (SARS). Biol Reprod. 2006; 74(2): 410-6.
- [26] Arnaout R, Lee RA, Lee GR, Callahan C, Yen CF, Smith KP, Arora R, Kirby JE. SARS CoV2 testing: The limit of detection matters. bioRxiv. 2020: 2020.06.02.131144.



